ALSO KNOWN AS STEELE–RICHARDSON–OLSZEWSKI SYNDROME
A physician-led, laboratory-verified treatment programme designed to slow functional decline, support postural and oculomotor stability, and preserve cognitive autonomy — tailored to the individual biology, disease stage and clinical profile of each PSP patient.
Request Medical ConsultationAbout the Condition
Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative tauopathy characterised by the abnormal accumulation of hyperphosphorylated tau protein in neurons and glial cells of the basal ganglia, brainstem and frontal cortex. This pathological tau deposition leads to progressive neuronal dysfunction and cell death in regions controlling eye movement, balance, gait, swallowing and executive cognition.
The hallmark clinical features include vertical gaze palsy (particularly downward gaze), early postural instability with backward falls, axial rigidity, pseudobulbar affect and progressive frontal-subcortical cognitive decline. Unlike Parkinson's disease, PSP responds poorly to levodopa therapy.
PSP affects approximately 5–7 people per 100,000 and is frequently misdiagnosed as Parkinson's disease in the early stages. Median survival from symptom onset is 6–9 years. There is no approved disease-modifying therapy. Current standard management is limited to symptomatic support — which is where our programme provides a structured biological intervention.
Richardson Syndrome (PSP-RS)
The classic and most common phenotype, accounting for approximately 55% of PSP cases. Characterised by early postural instability, vertical supranuclear gaze palsy, axial rigidity and frontal cognitive dysfunction. Falls typically occur within the first year of symptom onset. Progression tends to be faster than other PSP variants.
PSP-Parkinsonism (PSP-P)
Presents with asymmetric onset, tremor and initial partial response to levodopa — features that frequently lead to misdiagnosis as Parkinson's disease. Gaze palsy and postural instability develop later. Accounts for approximately 25–30% of PSP cases. Progression is generally slower than Richardson syndrome.
PSP-Pure Akinesia with Gait Freezing (PSP-PAGF)
Presents primarily with progressive gait freezing, micrographia and speech hesitation without significant rigidity or tremor in the early stages. Vertical gaze palsy may appear only years after onset. This phenotype has the slowest progression among PSP subtypes and is often underdiagnosed.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, disease stage, oculomotor and bulbar status, cognitive profile and overall clinical picture.
We do not offer a cure for PSP. Our programme is designed to target the biological mechanisms driving progression — with the clinical objective of stabilising function, slowing decline and improving daily quality of life.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2016 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
32
PSP patients treated since 2013
68%
measurable functional stabilisation on PSPRS at 3–6 months
−3.2 pts
average PSPRS score change at 6 months — vs. expected +5.5 pts natural progression
61%
sustained functional stability with average 2.5 years of follow-up
73%
showed improvement in one or more measured domains
65%
retained independence in basic activities of daily living (ADL) at 12 months
Motor & gait (postural stability, fall reduction, gait initiation, reduced freezing)
64%
Ocular & bulbar (vertical gaze range, saccadic control, swallowing safety, aspiration risk)
52%
Cognitive (frontal executive function, task completion, processing)
47%
Quality of life (daily activity tolerance, fatigue reduction, mood)
67%
3–8 weeks
Initial functional response
3–6 months
Clinically meaningful change
1.5–2.5 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on PSP phenotype, baseline PSPRS score, disease duration and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“The falls were the worst part. Four, five times a week, always backwards. After treatment in Warsaw, they dropped to maybe once every ten days. His neurologist in London couldn't explain it but confirmed the improvement was real.”
Patient's wife
PSP (Richardson syndrome) · United Kingdom
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
The BioCells Program
Our PSP programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's biological profile, disease stage and clinical priorities.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Important in PSP, where postural instability and swallowing compromise may make anaesthesia higher-risk.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets tau-driven neurodegeneration, not just symptoms
Rather than managing symptoms alone, our protocol targets neuroinflammation, oxidative stress and immune dysregulation — the biological mechanisms that amplify tau pathology and drive PSP progression.
Complements existing medication
Our programme is compatible with current PSP medications including any levodopa trials, amantadine or symptomatic treatments. Patients do not need to discontinue existing treatment before commencing our protocol.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
MSCs are multipotent regenerative cells with proven immunomodulatory and neuroprotective properties. They are among the most extensively studied cell types in regenerative medicine and have demonstrated safety across thousands of clinical applications worldwide.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 3-5 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are then expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in PSP
In PSP, chronic neuroinflammation driven by pathological tau aggregation is a primary mechanism of neuronal loss in the midbrain, brainstem and frontal regions. MSCs directly address this by suppressing the inflammatory cascade around affected neurons, creating a more stable microenvironment and supporting the biological conditions needed to preserve oculomotor, postural and cognitive function.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, PSP phenotype, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current PSPRS status, oculomotor and cognitive profile, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation, including neuroimaging and neuropsychological data. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured rehabilitation sessions with our specialist, adapted to your current postural stability, oculomotor function and cognitive status. Includes gaze training, balance work and swallowing therapy. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors PSPRS progression, functional status and overall well-being. Provides clinical guidance and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of PSP patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including swallowing deterioration or increased fall risk — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors postural stability, oculomotor function and cognitive status
Personalised rehabilitation programme
gaze training, balance therapy, swallowing exercises and frontal cognitive support adapted to current functional capacity
Medical-grade wearable monitoring
continuous physiological data collection including fall detection and activity tracking
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Our approach is based on the principle that biological regeneration requires time, monitoring and adjustment. The period following treatment is as medically important as the treatment itself. Consistent follow-up and structured rehabilitation are essential to sustaining and building on the initial clinical response.
Get Started
If you or someone you love has been diagnosed with Progressive Supranuclear Palsy, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current stage and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
